FGP
TMDX icon

Freestone Grove Partners’s Transmedics TMDX Stock Holding History

Freestone Grove Partners’s Portfolio TMDX Stock Details TMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Buy
+3,537
New +$299K ﹤0.01% 785
2025
Q1 		– Sell
-3,865
Closed -$241K – 786
2024
Q4 		$241K Buy
+3,865
New +$360K ﹤0.01% 508

Other funds holding TMDX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $13.8B AUM 163.97% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return

Freestone Grove Partners's TMDX Position: Q2 2026 in Review

Freestone Grove Partners opened a new position in Transmedics (TMDX) in Q2 2026: 3,537 shares worth $235K. The stake represents ﹤0.01% of the portfolio and ranks #785 among its holdings. This is a return to the name: Freestone Grove Partners previously reported a position in TMDX as recently as Q4 2024.

Freestone Grove Partners first reported a position in TMDX in Q4 2024 and has held it in 2 quarters since. The position peaked at $241K in Q4 2024. 375 funds tracked by Wall St. Rank hold TMDX as of Q2 2026.

  • Freestone Grove Partners held 3,537 shares of Transmedics worth $235K as of Q2 2026.
  • Transmedics was a new Freestone Grove Partners position in Q2 2026.
  • Transmedics made up ﹤0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #785 holding.
  • Freestone Grove Partners first reported a position in Transmedics in Q4 2024 and has held it in 2 quarters since.
  • Freestone Grove Partners's Transmedics position peaked at $241K in Q4 2024.
  • 375 funds tracked by Wall St. Rank held Transmedics as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.